OPKO Health, Inc. (NASDAQ:OPK) Receives Consensus Rating of “Hold” from Brokerages

Shares of OPKO Health, Inc. (NASDAQ:OPK) have been assigned a consensus recommendation of “Hold” from the six brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $1.55.

Several analysts recently weighed in on the company. Barrington Research downgraded OPKO Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 29th. Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings upgraded OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 18th.

OPKO Health Stock Performance

OPK stock opened at $1.44 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.61 and a quick ratio of 3.17. The business has a 50-day moving average price of $1.21 and a 200 day moving average price of $1.25. The company has a market capitalization of $1.09 billion, a P/E ratio of -5.33 and a beta of 1.50. OPKO Health has a 1-year low of $0.98 and a 1-year high of $1.60.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings data on Tuesday, April 28th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $124.20 million during the quarter, compared to the consensus estimate of $130.51 million. OPKO Health had a negative return on equity of 16.78% and a negative net margin of 36.63%.The firm’s quarterly revenue was down 17.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.10) earnings per share. As a group, equities research analysts forecast that OPKO Health will post -0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On OPKO Health

Large investors have recently added to or reduced their stakes in the company. UBS Group AG raised its holdings in OPKO Health by 12.1% in the fourth quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock worth $6,745,000 after purchasing an additional 577,248 shares in the last quarter. Hsbc Holdings PLC bought a new position in OPKO Health in the first quarter worth about $273,000. State of Wyoming bought a new position in OPKO Health in the first quarter worth about $190,000. SG Americas Securities LLC raised its holdings in OPKO Health by 62.6% in the first quarter. SG Americas Securities LLC now owns 87,846 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 33,824 shares in the last quarter. Finally, Abel Hall LLC bought a new position in OPKO Health in the first quarter worth about $38,000. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.